Aflibercept iso-osmotic ophthalmic
CAS862111-32-8
Aflibercept iso-osmotic ophthalmic (CAS 862111-32-8, C4318H6788N1164O1304S32) is supplied by ChemSigma for research and manufacturing, with specification, analytical methods and batch documentation available on request.
- CAS No.
- 862111-32-8
- Formula
- C4318H6788N1164O1304S32
- Mol. weight
- 96898.57 g/mol
Chemical Specifications
Identifiers
| CAS number | 862111-32-8 |
|---|---|
| Product name | Aflibercept iso-osmotic ophthalmic |
| Chinese name | 阿柏西普 |
| Synonyms | Aflibercept iso-osmotic ophthalmic; VEGF trap; VEGF Trap R1R2 |
| Molecular formula | C4318H6788N1164O1304S32 |
| Molecular weight | 96898.57 g/mol |
Packaging, Storage & Transport
| Available pack sizes | 5kg, 1kg, 500g, 100g, 50g, 10g |
|---|
Read the current safety data sheet before handling. Packaging can be adapted to the order quantity and destination.
Frequently Asked Questions
What is the CAS number of Aflibercept iso-osmotic ophthalmic?
The CAS Registry Number of Aflibercept iso-osmotic ophthalmic is 862111-32-8. Aflibercept iso-osmotic ophthalmic is also known as Aflibercept iso-osmotic ophthalmic; VEGF trap; VEGF Trap R1R2.
What is the molecular formula and molecular weight of Aflibercept iso-osmotic ophthalmic?
The molecular formula of Aflibercept iso-osmotic ophthalmic is C4318H6788N1164O1304S32, and its molecular weight is 96898.57 g/mol.
How can I request a quotation for Aflibercept iso-osmotic ophthalmic?
Send an inquiry for Aflibercept iso-osmotic ophthalmic (CAS 862111-32-8) with the required quantity, target specification, destination country and any documentation requirements. ChemSigma will confirm availability, packaging, lead time and price.
Request a Quote for Aflibercept iso-osmotic ophthalmic
Tell us the required quantity, target specification, destination country and any documentation requirements. We will confirm availability, packaging, lead time and price.
Need custom synthesis or scale-up? Our group company CKS Technology offers custom synthesis, process development and scale-up.